Mirvaso (brimonidine tartrate) / Galderma - LARVOL DELTA

Exploring New Dimensions in Longitudinal Rosacea Management. (PubMed, Dermatol Ther (Heidelb)) - "Deepening the understanding of the condition as a chronic, yet eminently manageable one, will help empower patients with rosacea and their dermatologists alike. The REACH GSC project was initiated and funded by Galderma."

Journal • Review • Dermatology • Inflammation • Rosacea

CD21 Things can only get redder! Two cases of allergic contact dermatitis to topical brimonidine tartrate gel. (PubMed, Br J Dermatol) - "Allergic contact blepharitis to brimonidine eye drops is recognized and, more recently, case reports have described patients developing ACD to topical brimonidine gel [Bangsgaard N, Fischer LAN, Zachariae C. Sensitization to and allergic contact dermatitis caused by Mirvaso® (brimonidine tartrate) for treatment of rosacea - 2 cases...He had been using topical Elocon cream daily (mometasone furoate 0.1%) and was diagnosed with steroid-induced rosacea. He was prescribed oral doxycycline, ivermectin cream and brimonidine gel...We would like to raise awareness that in addition to rebound erythema, topical brimonidine gel is also a cause of severe facial ACD. Patch testing to the patient's own medicaments should be performed in suspected cases."

Journal • Allergy • Contact Dermatitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Ocular Inflammation • Ophthalmology • Rosacea • CD21

TAR-0520 GEL, A NOVEL TREATMENT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED SKIN TOXICITIES (MASCC-ISOO 2025) - "The PK assessment conducted under maximized conditions confirmed slow release of the active while yielding systemic exposures similar to those exhibited by marketed products that contain lower brimonidine concentrations (Alphagan eyedrops 0.2% or Mirvaso gel 0.5%)...Conclusions TAR-0520 gel is a safe topical treatment developed for the prevention of skin toxicities induced by chemotherapies: where applied, it protects the skin by decreasing the bioavailability of a systemic drug to levels below the threshold inducing side-effects. EGFR-induced folliculitis, chemotherapy-induced alopecia or hand-foot syndrome are target indications in TAR-0520 gel development program with phase 2 studies in cancer patients initiated in 2024."

Alopecia • Dermatology • Immunology • Oncology • Pain • EGFR

Symptomatic bradycardia associated with topical brimonidine gel (Mirvaso) administration: a case report. (PubMed, Eur Heart J Case Rep) - "This is owing to the increased risk of systemic absorption, which as in this case report, may present with bradycardia. This case reiterates the importance of completing a full medication history including all topical and parenteral medications in patients with arrhythmia."

Journal • Atrial Fibrillation • Benign Prostatic Hyperplasia • Cardiovascular • Dermatology • Glaucoma • Hypotension • Ophthalmology • Rosacea

Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape. (PubMed, Drugs) - "It evaluates the efficacy, safety, and tolerability of various US Food and Drug Administration (FDA)-approved agents used for rosacea treatment, including E-BPO cream, metronidazole gel, azelaic acid gel and foam, ivermectin cream, minocycline foam, oral doxycycline, brimonidine gel, and oxymetazoline HCl cream...Further research is necessary to determine the exact role of E-BPO 5% in the therapeutic landscape for rosacea. However, based on available evidence, E-BPO 5% shows potential as a valuable treatment option for managing inflammatory lesions of rosacea, and it may offer benefits to patients including: rapid onset of action, demonstrated efficacy by Week 2, excellent tolerability, and sustained long-term results for up to 52 weeks of treatment."

Journal • Review • Dermatology • Rosacea

Comparison table: Some topical drugs for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Drugs for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Aqueous Humor Dynamics and Brimonidine (clinicaltrials.gov) - P1 | N=35 | Completed | Sponsor: University of Nebraska | Phase classification: P=N/A ➔ P1

Phase classification • Cardiovascular • Glaucoma

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia (clinicaltrials.gov) - P3 | N=170 | Not yet recruiting | Sponsor: Visus Therapeutics

New P3 trial • Ophthalmology

Minocycline foam (Zilxi) for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Mirvaso in Use Study (clinicaltrials.gov) - P4; N=250; Recruiting; Sponsor: Galderma Laboratories, L.P.; Trial primary completion date: Jan 2015 ->Apr 2015

Trial primary completion date • Biosimilar

The Effect of Brimonidine (clinicaltrials.gov) - P4; N=13; Completed; Sponsor: Wake Forest University Health Sciences; Active, not recruiting ➔ Completed

Clinical • Trial completion

Case Report: Allergic Contact Dermatitis to Topical Brimonidine Demonstrated With Patch Testing: Insights on Evaluation of Brimonidine Sensitization. (PubMed, J Cutan Med Surg) - No abstract available.

Clinical • Journal

The Effect of Brimonidine (clinicaltrials.gov) - P4; N=13; Active, not recruiting; Sponsor: Wake Forest University Health Sciences; Not yet recruiting ➔ Active, not recruiting; N=20 ➔ 13

Clinical • Enrollment change • Enrollment closed

The Effect of Brimonidine (clinicaltrials.gov) - P4; N=20; Not yet recruiting; Sponsor: Wake Forest University Health Sciences

Clinical • New P4 trial

Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations (clinicaltrials.gov) - P3; N=6; Terminated; Sponsor: The Hospital for Sick Children; N=20 ➔ 6; Recruiting ➔ Terminated; Poor enrollment, lack of feasibility

Clinical • Enrollment change • Trial termination

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists (clinicaltrials.gov) - P1; N=20; Completed; Sponsor: University of California, San Francisco; Recruiting ➔ Completed

Trial completion

Pilocarpine and Brimonidine in Patients With Monofocal Lenses (clinicaltrials.gov) - P1; N=33; Recruiting; Sponsor: Massachusetts Eye and Ear Infirmary

Clinical • New P1 trial

BRIMOCAN: The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients (clinicaltrials.gov) - P2; N=2; Terminated; Sponsor: Heinrich-Heine University, Duesseldorf; N=24 ➔ 2; Trial completion date: Apr 2019 ➔ Dec 2018; Recruiting ➔ Terminated; Trial primary completion date: Apr 2018 ➔ Dec 2018; It is no longer practicable to complete the trial

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination